Gary D. Stoner

Dr. Gary D. Stoner

Montana State University, MT, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2019 in Molecules
Verified
Journal Article
Open access
PDF file
JLJohn Lechner
John Lechner
Gary D. StonerGary D. Stoner
Gary D. Stoner
Carcinogenesis is the process whereby a normal cell is transformed into a neoplastic cell. This action involves several steps starting with initiation and followed by promotion and progression. Driving these stages are oxidative stress and inflammation, which in turn encompasses a myriad of aberrant gene expressions, both within the transforming cell population and the cells within the surrounding lesion. Chemoprevention of cancer with bioreactive foods or their extracted/purified components occurs via normalizing these inappropriate gene activities. Various foods/agents have been shown to affect different gene expressions. In this review, we discuss whereby the chemoprevention activities of the red beetroot itself may disrupt carcinogenesis and the activities of the water-soluble betalains extracted from the plant.

19 February 2020 in Efood
Verified
Journal Article
Open access
PDF file
LWLi‐Shu Wang
Li‐Shu Wang
CECarla Elena Echeveste
Carla Elena Echeveste
JYJianhua Yu
Jianhua Yu
YHYi‐Wen Huang
Yi‐Wen Huang
JLJohn Lechner
John Lechner
Gary D. StonerGary D. Stoner
Gary D. Stoner
More than 50% of the world’s population is infected with Helicobacter pylori. H. pylori is the major causative agent of gastric ulcers and gastric cancer. H. pylori eradication using antibiotics either alone or together with a proton pump inhibitor is the primary strategy to decrease the incidence of gastric cancer. Although eradication therapy is effective, there are significant adverse effects and more importantly, resistance to antibiotics occurs, which represents a major therapeutic challenge. Multiple natural products have been shown to suppress H. pylori both in vitro and in animal model systems. However, only a handful of natural products have been evaluated in human clinical trials. The focus of this review is to summarize the results of published human clinical trials to assess the ability of natural products to reduce or eliminate H. pylori infections. Current evidence suggests that these products appear to have great potential to be developed as pharmaceutical candidates for eradication of H. pylori, hopefully both antibiotic‐sensitive and antibiotic‐resistant strains. Frequent consumption of locally produced foodstuff for controlling H. pylori infection in different countries around the world may well be a feasible long‐term solution to fight against this worldwide prevalent pathogen.